IRLAB Appoints Janne Backman as New Chairman of the Board
Gothenburg, September 24, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, announces that Jan-Fredrik (“Janne”) Backman today assumes the role of Chairman of the Board. He was elected Vice Chairman at the 2026 Annual General Meeting and now succeeds Carola Lemne, who announced back in the spring that she intended to step down from the position in September.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
CEO interview with Kristina Torfgård and CFO Gustaf Albèrt at Redeye
Redeye interviewed CEO Kristina Torfgård and CFO Gustaf Albèrt about IRLAB’s announced rights issue and the company’s priorities going forward. Published on June 16, 2026. Watch the video on Vimeo
Read More >